National Institute of Allergy and Infectious Diseases (NIAID): Malaria, Falciparum trials
The registry lists 28 Malaria, Falciparum studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 1 are open to participants now and 1 have results posted.
Phase 1 13Phase 2 2Phase 3 1Phase 4 1No phase 11(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine CandidatesRecruitingNCT02471378
- Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in MaliCompletedNCT05135273Phase 1Results posted
- First-in-Human PfSPZ-LARC2 Vaccination/CHMICompletedNCT06735209Phase 1
- Artemether-lumefantrine Resistance Monitoring in Children With Uncomplicated Plasmodium Falciparum Malaria in MaliCompletedNCT02645604
- Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in CambodiaCompletedNCT02612545Phase 1
- Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and MaliCompletedNCT02334462Phase 1
- Malaria Transmission Studies in MaliCompletedNCT01829737
- Artemisinin-resistant Malaria in CambodiaCompletedNCT01736319
- EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum MalariaCompletedNCT01169077Phase 1
- Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria ImmunityCompletedNCT01160562
- EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune AdultsCompletedNCT01026246Phase 1
- Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and MaliCompletedNCT00889616Phase 1
- Innate and Acquired Resistance to Plasmodium Falciparum Malaria in MaliCompletedNCT00669084
- ICC-1132 - Candidate Vaccine Against P Falciparum MalariaCompletedNCT00587249Phase 1
- Plasmodium Resistance in A. GambiaeCompletedNCT00466557
- Malaria Transmission and Immunity in Highland KenyaCompletedNCT00393757
- CS DNA MVA Trial in Mampong, GhanaWithdrawnNCT00377494Phase 1
- Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered IntramuscularlyCompletedNCT00347555Phase 1
- AMA1-C1/Alhydrogel + CpG 7909 for MalariaCompletedNCT00344539Phase 1
- Experimental Vaccine for Malaria in Adults in MaliCompletedNCT00343005Phase 1
- Experimental Vaccine for Plasmodium Falciparum MalariaCompletedNCT00340431Phase 1
- Malaria Prevalence in ChildrenCompletedNCT00322816
- Time to Infection With Malaria ParasitesCompletedNCT00322738
- Fetal Immunity to Falciparum MalariaCompletedNCT00314899
- SP Resistance and Falciparum Malaria TransmissionWithdrawnNCT00299247Phase 3
- Azithromycin Combination Therapy for MalariaCompletedNCT00299208Phase 2
- Pentoxifylline in Children With MalariaTerminatedNCT00133393Phase 2
- CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in MalawiCompletedNCT00125489Phase 4